High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: Preliminary clinical result and testable hypothesis

Oncotarget

Volumn 6, Issue 21, 2015, Pages 18674-18682

  Wang, Chun yu ^a   Deng, Jia ying ^a   Cai, Xu wei ^b   Fu, Xiao long ^b   Li, Yuan ^a   Zhou, Xiao yan ^a   Wu, Xiang hua ^a   Hu, Xi chun ^a   Fan, Min ^a   Xiang, Jia qing ^a   Zhang, Ya wei ^a   Chen, Hai quan ^a   Perez, Rolando ^c   Jiang, Guo liang ^a   Zhao, Kuai le ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

EGFR; Esophageal squamous cell carcinoma; Monoclonal antibody; p Akt; p Erk

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB; PROTEIN KINASE B; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL TIME; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84938817169     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4367     Document Type: Article

References (38)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87-108.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and Participants MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006; 355:11-20.
3. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A and Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology. 2011; 12:681-692.
4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine. 2012; 366:2074-2084.
5. Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, Kajiura K, Minato T, Bando Y and Tangoku A. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Annals of surgical oncology. 2012; 19:757-765.
6. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. International journal of cancer Journal international du cancer. 2006; 118:1173-1180.
7. Wheeler DL, Dunn EF and Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature reviews Clinical oncology. 2010; 7:493-507.
8. Chua DT, Nicholls JM, Sham JS and Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. International journal of radiation oncology, biology, physics. 2004; 59:11-20.
9. Liang K, Ang KK, Milas L, Hunter N and Fan Z. The epidermal growth factor receptor mediates radioresistance. International journal of radiation oncology, biology, physics. 2003; 57:246-254.
10. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N and Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. British journal of cancer. 2005; 93:107-115.
11. Milas L, Fan Z, Andratschke NH and Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. International journal of radiation oncology, biology, physics. 2004; 58:966-971.
12. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T and Griffiths G. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology. 2013; 14:627-637.
13. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner RA, Gamble T, Peachey L, Davoudianfar M, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. The Lancet Oncology. 2014; 15:894-904.
14. Rodriguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodriguez E, Gracias E, Mulen B, Wilkinson B, de Armas EL, Perez K, Pineda I, Frometa M, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer biology&therapy. 2010; 9:343-349.
15. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized antiepidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer biology & therapy. 2012; 13:600-605.
16. Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Lai ST, Jiang GL and Zhao KL. Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. International journal of clinical oncology. 2014; 19:297-302.
17. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A and Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007; 109:658-667.
18. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C and Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24:1612-1619.
19. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F and Peschel C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). British journal of cancer. 2010; 102:500-505.
20. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12:4283-4287.
21. Shigaki H, Baba Y, Watanabe M, Miyake K, Murata A, Iwagami S, Ishimoto T, Iwatsuki M, Yoshida N and Baba H. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Annals of surgical oncology. 2013; 20 Suppl 3:S485-491.
22. Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. OncoTargets and therapy. 2013; 6:1589-1596.
23. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hofler H, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC cancer. 2011; 11:509.
24. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD and Abbruzzese JL. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24:4922-4927.
25. Fichter CD, Timme S, Braun JA, Gudernatsch V, Schopflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M and Lassmann S. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. International journal of cancer Journal international du cancer. 2014; 135:1517-1530.
26. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R and Kono K. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. Journal of immunology (Baltimore, Md: 1950). 2013; 191:6261-6272.
27. Byzova T, Goldman C, Pampori N, Thomas K, Bett A, Shattil S and Plow E. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell. 2000; 6:851-860.
28. Rho O, Kim DJ, Kiguchi K and Digiovanni J. Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Molecular carcinogenesis. 2011; 50:264-279.
29. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW and Baba HA. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2004; 17:15-21.
30. Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, Okada K, Matsuyama J, Makari Y, Sohma I, Takiguchi S, Fujiwara Y and Monden M. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncology reports. 2008; 19:1099-1107.
31. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2:1352-1367.
32. Li Y, Choi PS and Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 2014; 5:7986-7987.
33. Holien T and Sundan A. Oncogene addiction to c-MYC in myeloma cells. Oncotarget. 2012; 3:739-740.
34. Mancias JD and Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget. 2011; 2:1302-1306.
35. Chong CR and Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature medicine. 2013; 19:1389-1400.
36. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging. 2012; 4:350-358.
37. Yarden Y and Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature reviews Cancer. 2012; 12:553-563.
38. Jiang D, Li X, Wang H, Shi Y, Xu C, Lu S, Huang J, Xu Y, Zeng H, Su J, Hou Y and Tan L. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC cancer. 2015; 15:377.